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Abstract: Obesity is a chronic disease of multifactorial origin and can be defined as an 
increase in the accumulation of body fat. Adipose tissue is not only a triglyceride storage 
organ, but studies have shown the role of white adipose tissue as a producer of certain 
bioactive  substances  called  adipokines.  Among  adipokines,  we  find  some  inflammatory 
functions, such as Interleukin-6 (IL-6); other adipokines entail the functions of regulating 
food intake, therefore exerting a direct effect on weight control. This is the case of leptin, 
which  acts  on  the  limbic  system  by  stimulating  dopamine  uptake,  creating  a  feeling  of 
fullness. However, these adipokines induce the production of reactive oxygen species (ROS), 
generating a process known as oxidative stress (OS). Because adipose tissue is the organ 
OPEN ACCESS Int. J. Mol. Sci. 2011, 12                       
 
 
3118 
that secretes adipokines and these in turn generate ROS, adipose tissue is considered an 
independent factor for the generation of systemic OS. There are several mechanisms by 
which  obesity  produces  OS.  The  first  of  these  is  the  mitochondrial  and  peroxisomal 
oxidation of fatty acids, which can produce ROS in oxidation reactions, while another 
mechanism  is  over-consumption  of  oxygen,  which  generates  free  radicals  in  the 
mitochondrial respiratory chain that is found coupled with oxidative phosphorylation in 
mitochondria. Lipid-rich diets are also capable of generating ROS because they can alter 
oxygen metabolism. Upon the increase of adipose tissue, the activity of antioxidant enzymes 
such as superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx), was 
found to be significantly diminished. Finally, high ROS production and the decrease in 
antioxidant  capacity  leads  to  various  abnormalities,  among  which  we  find  endothelial 
dysfunction, which is characterized by a reduction in the bioavailability of vasodilators, 
particularly nitric oxide (NO), and an increase in endothelium-derived contractile factors, 
favoring atherosclerotic disease. 
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1. Introduction 
Obesity is a chronic disease of multifactorial origin that develops from the interaction of social, 
behavioral,  psychological,  metabolic,  cellular,  and  molecular  factors  [1].  It  is  the  condition  under 
which adipose tissue is increased and can be defined as an increase in body weight that results in 
excessive fat accumulation. The World Health Organization (WHO) defines obesity as a body mass 
index (BMI) > 30 and defines overweight as with a BMI of 25 [2]. 
2. Etiological Factors 
Fundamentally, obesity is the result of excessive energy consumption compared with the energy 
expended; in children, increased consumption of fats and sugars and lack of physical activity have 
been linked with obesity [2]. 
The basic hypothesis of the cause of the disease is the existence of the ―thrifty gene theory‖, which 
suggests that some populations may have genes that determine increased fat storage, the latter when 
experiencing  periods  of  starvation,  thus  providing  a  survival  advantage;  but  under  current 
circumstances, overstocking of fat results in obesity and Type 2 diabetes mellitus (T2DM) [2]. On the 
other hand, it has been postulated that in the early stages of our evolution, highly effective systems 
were developed to collect the limited energy available, leading to the appearance of adipose tissue. The 
lack of industrial development meant long hours of exhaustive physical exercise to achieve limited 
amounts of food. This energy would accumulate efficiently for later use. 
Changes in lifestyle and diet have resulted in an increase in the number of obese subjects; obesity 
has been regarded as an important factor in causing various health problems [3]. Another theory for 
explaining the development of obesity is known as the fetal origins hypothesis of chronic diseases. Int. J. Mol. Sci. 2011, 12                       
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This suggests that poor maternal nutrition and poor fetal growth are risk factors for developing chronic 
diseases that affect the programming of body structure, physiology, and metabolism [4]. The central 
nervous system (CNS), by means of signals, regulates appetite, energy intake, and weight gain; obesity 
can result from a failure of these signaling pathways [2]. 
3. Epidemiology 
Obesity  is  considered  the  largest  public  health  problem  worldwide,  especially  in  industrialized 
countries [5]. Obesity increases mortality and the prevalence of cardiovascular diseases, diabetes, and 
colon cancer [6]. Substantial literature has emerged that shows that overweight and obesity are major 
causes of co-morbidities, including T2DM, cardiovascular diseases, various cancers, and other health 
problems, which can lead to further morbidity and mortality. The related health-care costs are also 
substantial.  Therefore,  a  public  health  approach  to  develop  population-based  strategies  for  the 
prevention of excess weight gain is of great importance. However, public health intervention programs 
have had limited success in tackling the rising prevalence of obesity. This paper reviews the definition 
of overweight and obesity and variations regarding age and ethnicity and health consequences and 
factors contributing to the development of obesity, and presents a critical review of the effectiveness of 
current public health strategies for risk factor reduction and obesity prevention [7]. 
4. Adipose Tissue 
Human adipose tissue is divided into brown adipose tissue, which possesses multilocular adipocytes 
with abundant mitochondria that express high amounts of uncoupling protein 1 (UCP-1), which is 
responsible  for  the  thermogenic  activity  of  this  tissue  [8],  and  white  adipose  tissue,  which  is 
responsible for fat storage. Among the characteristics of white adipose tissue, we found that it consists 
of different cell types such as fibroblasts, preadipocytes, mature adipocytes, and macrophages. This 
tissue is very heterogeneous according to its visceral or subcutaneous location [9]. 
In animals with obesity, there is a huge increase in white fat deposits due to the hyperplasia and 
hypertrophy of their adipocytes [8]. Hypertrophic-hyperplastic adipocytes exhibit a lower density of 
insulin receptors and a higher beta-3 adrenergic receptor, which facilitates the diapedesis of monocytes 
to visceral adipose stroma, initiating a proinflammatory cycle between adipo- and monocytes [10]. 
Adipose tissue is not only a triglyceride (TG)-storage tissue; studies in recent years have shown the 
role  of  white  adipose  tissue  as  a  producer  of  certain  substances  with  endocrine,  paracrine,  and 
autocrine action [2]. These bioactive substances are denominated adipokines or adipocytokines, among 
which  are  found  plasminogen  activator  inhibitor-1  (PAI-1),  tumor  necrosis  factor-alpha  (TNF-α), 
resistin, leptin, and adiponectin [11]. These substances derive primarily from white adipose tissue and 
play a role in the homeostasis of various physiological processes (Figure 1). Int. J. Mol. Sci. 2011, 12                       
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Figure 1. This figure depicts the major adipokines and their roles. Adipose tissue produces 
several adipokines that exert metabolic effects, both in central and in peripheral tissues. 
The production of these adipokines is regulated by insulin, cathecholamines, and adiposity. 
TNF-alpha:  Tumor  necrosis  factor-alpha;  IL-6:  Interleukin.  (Courtesy  of  Cristina 
Ferná ndez-Mejí a, Ph.D.). 
 
5. Adipokines and Metabolic Homeostasis 
5.1. Leptin 
Leptin was discovered in 1994. It is a hormone secreted mainly by adipocytes in direct proportion to 
the mass of adipose-tissue TG content and the nutritional condition [3]. In order to be secreted by 
adipose tissue, leptin circulates in plasma bound to plasma proteins, entering by diffusion into the CNS, 
through capillary binding in the median eminence and by saturable transport across the choroid plexus 
receiver. In the ventro-medial nucleus of the hypothalamus, leptin stimulates cytokine receptor kinase  
2  (CK2),  the  synthesis  of  melanocyte-stimulating  hormone  and  by  cocaine-amphetamine-regulated 
transcriptor  (CART)  molecules  that,  via  paracrine,  stimulate  receptors  3  and  4  of  the  lateral 
melanocortin nucleus, causing satiety [2,11]. 
Leptin inhibits lipogenesis and stimulates lipolysis, reducing intracellular lipid levels in skeletal muscle, 
liver,  and  pancreatic  beta  cells,  thereby  improving  insulin  sensitivity.  The  limbic  system  stimulates 
dopamine reuptake, thereby blocking the pleasure of eating and, through the locus coeruleus nucleus, 
activates the sympathetic nervous system, which leads to increased resting energy expenditure [11]. 
Catecholamines influence the production of leptin, and other leptin production regulators comprise 
the glucocorticoids [2], although it has been postulated that the main determinant of leptin secretion is Int. J. Mol. Sci. 2011, 12                       
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glucose metabolism, because the concentration of circulating leptin diminishes under fasting or caloric 
restriction conditions and increases in response to food intake [8]. Obesity is associated with increased 
leptin levels; as a result, it has been postulated that the apparent decrease in anorexigenic effects and 
weight loss are the result of a mechanism of resistance to it [11]. 
In  inflammation,  leptin  acts  directly  on  macrophages  to  increase  phagocytic  activity,  and 
proinflammatory cytokine production also exerts an effect on T-cells, monocytes, neutrophils, and 
endothelial  cells.  When  leptin  is  administered,  increased  levels  of  C-reactive  protein  (CRP)  are 
produced, thus proving its inflammatory effect [12]. When there is weight loss, circulating levels of the 
hormone  are  reduced,  and  in  turn,  these  levels  reduce  the  plasma  levels  of  obesity-associated 
inflammatory markers [13]. 
In addition to promoting oxidative stress and vascular inflammation, leptin stimulates proliferation 
and  migration  of  endothelial  cells  and  smooth  muscle  cells,  thus  favoring  the  development  of 
atherosclerosis [14]. It is noteworthy that leptin can also be produced in placenta, spinal cord, stomach, 
muscle, and perhaps in brain, which increases the regulatory role of this hormone [2]. 
5.2. Tumor Necrosis Factor Alpha (TNF-α) 
TNF-α  was  one  of  the  first  cytokines  identified  and  is  involved  in  the  systemic  inflammatory 
response; additionally, it has also has been linked with the development of insulin resistance, obesity, and 
diabetes [9]. It is produced mainly by monocytes, lymphocytes, adipose tissue, and muscle [15] and its 
irregular production participates in the pathogenesis of the obesity-associated metabolic syndrome. 
TNF-α activity on insulin resistance can be explained as follows: it increases the release of free 
fatty acids  (FFA)  in  adipocytes;  it  blocks  the  synthesis  of  adiponectin,  which  possesses  
insulin-sensitizing activity in high concentrations in adipose tissue, and it interferes with the activity of 
tyrosine-residue  phosphorylation  activity  in  the  first  substrate  of  the  insulin  receptor,  which  is 
necessary for progression of the intracellular signal of the hormone [3]. The TNF-α activates nuclear 
factor κB (NF-κ B), resulting in the increased expression of adhesion molecules on the surface of 
endothelial cells and vascular smooth muscle cells, resulting in an inflammatory state in adipose tissue, 
endothelial dysfunction, and, ultimately, atherogenesis [3]. 
5.3. Interleukin 6 (IL-6) 
This  is  a  cytokine  that  exerts  many  effects,  ranging  from  defense  to  inflammation  and  tissue  
damage [11]. It is produced both by macrophages and adipocytes [14], and by immune system cells, 
fibroblasts, endothelial cells, and skeletal muscle [9]. Circulating levels of IL-6 correlate with BMI, 
insulin resistance, and intolerance to carbohydrates [3]. IL-6 also influences glucose tolerance through 
negative regulation of visfatin; in addition, it antagonizes the secretion of adiponectin [11], and in 
animal  model,  it  elevates  TG  levels  by  enhancing  gluconeogensis  and  glycogenolysis  and  
inhibiting glycogenesis. Int. J. Mol. Sci. 2011, 12                       
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5.4. Angiotensinogen/PAI-1 
Angiotensinogen may play an important role in the regulation of adipose tissue blood supply and 
the flow of fatty acids from the same [8]. It is expressed in multiple cell types within adipose tissue; its 
expression and secretion are higher in visceral tissue than in subcutaneous tissue, and its high levels 
correlate with metabolic syndrome [11]. 
Plasminogen activator inhibitor (PAI-1) is the first physiological inhibitor of plasminogen activators 
in the blood and contributes to thrombus formation and the development of chronic cardiovascular 
disease. PAI-1 can play an important role in the regulation of adipose tissue blood supply and the flow 
of fatty acids from it. Plasma levels of PAI-1 are regulated by the accumulation of visceral fat, and a 
high concentration of PAI-1 is associated with insulin resistance as well as with pro-inflammatory 
cytokines [2]. 
5.5. Adiponectin 
Adiponectin  is  a  protein  that  is  structurally  homologous  to  collagens  VIII  and  X  and  of 
complementary system factor C1q, also known as ADIPOQ, Acrp, APM1, and GBP. Adiponectin 
expression and secretion is unique to differentiated adipocytes [8] and has regulatory actions on energy 
homeostasis,  glucose  and  lipid  metabolism,  and  anti-inflammatory  action  [2].  In  contrast  to  other 
adipokines,  adiponectin  expression  and  plasma  concentrations  are  not  increased,  but  are  rather 
decreased in a wide variety of diseases presenting insulin resistance and obesity [9]. High levels of this 
adipokine are related with weight loss [2] and, in addition, adiponectin improves insulin sensitivity, 
decreases the flow of free fatty acids and increases their oxidation, inhibits major gluconeogenic liver 
enzymes, reduces hepatic release of glucose and muscle, and stimulates glucose utilization and fatty 
acid oxidation [3]. Adiponectin shows high anti-inflammatory and antiatherogenic powers because it 
inhibits the adhesion of monocytes to endothelial cells, the transformation of macrophages into foam 
cells  and  endothelial  cell  activation,  inhibits  TNF-α  expression  [2],  decreases  CRP  levels,  and 
increases  nitric  oxide  (NO)  production  in  endothelial  cells  [16].  Its  globular  isoform  inhibits  cell 
proliferation  and  production  of  ROS  induced  by  low-density  lipoprotein  (LDL)  oxidase  during 
atheromatous plaque formation [17]. In general, adiponectin deficiency results in NO reduction in the 
vascular walls and promotes leukocyte adhesion, causing chronic vascular inflammation [16]. Finally, 
it was observed that TNF-α and IL-6 are potent inhibitors of adiponectin expression and secretion [9]. 
5.6. Adipsin 
Adipsin is a relatively small serine protease that is secreted by adipocytes and that is positively 
related with adiposity, insulin resistance, dyslipidemia, and cardiovascular disease. Adipsin appears to 
regulate the rate at which fatty acids from Lipoprotein lipase (LPL) are taken up by adipocytes and 
subsequently converted into TG. The molecular basis of the pathogenesis of obesity-linked disorders 
has not been fully elucidated. Adipose tissue serves not only as an energy storage organ, but also as an 
endocrine  organ.  It  releases  many  factors  with  autocrine,  paracrine,  and  endocrine  functions. 
Adipokines such as adipsin are biologically active molecules produced by adipose tissue. They play a 
role in energy homeostasis, and in glucose and lipid metabolism [18]. Int. J. Mol. Sci. 2011, 12                       
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5.7. Resistin 
Resistin (RSTN) is an adipokine produced by mature adipocytes and macrophages, and it has been 
postulated  that  resistin  might  comprise  the  link  between  obesity  and  insulin  resistance  [8].  This 
adipokine belongs to the family of secreted proteins termed cysteine-rich Found in inflammatory zone 
(FIZZ), and the approved gene symbol is RETN. It possesses hyperglycemic properties; circulating 
resistin levels are proportional to the degree of adiposity but are not related with the degree of insulin 
resistance [9]. RSTN is a link to the inflammatory environment due to its predominant production of 
monocytes and its correlation with IL-6 levels [11]. 
On the other hand, Type 2 diabetes mellitus (T2DM), characterized by target-tissue resistance to 
insulin, is epidemic in industrialized societies and is strongly associated with obesity; however, the 
mechanism by which increased adiposity causes insulin resistance is unclear. Adipocytes secrete a 
unique signaling molecule, which we have denominated resistin (for resistance to insulin). Circulating 
resistin levels are decreased by the anti-diabetic drug rosiglitazone and are increased in diet-induced 
and genetic forms of obesity. Administration of the anti-resistin antibody improves blood sugar and 
insulin  action  in  mice  with  diet-induced  obesity.  Moreover,  treatment  of  normal  mice  with 
recombinant resistin impairs glucose tolerance and insulin action. Insulin-stimulated glucose uptake by 
adipocytes is enhanced by neutralization of resistin and is reduced by resistin treatment. Thus, resistin 
is a hormone that potentially links obesity with diabetes [19,20]. 
5.8. Other Adipokines 
Visfatin is an important adipocytokine. Concentrations of this adipokine are increased in humans 
with abdominal obesity and Diabetes mellitus (DM). Its increased concentration in obesity could be a 
compensatory response in an attempt to maintain blood euglycemia. The regulation of its synthesis is 
stimulated  by  glucocorticoids  and  inhibited  by  TNF-α,  IL-6,  growth  hormone,  and  β-adrenergic 
receptor agonists [21]. 
Visfatin stimulates adipocytes differentiation, promotes the accumulation of TG from glucose, and 
induces expression of genes encoding for diacylglycerol acyltransferase and for adiponectin by means 
of a reduction in glucose release from adipocytes [11]. 
Another adipokine is omentin, a peptide secreted by visceral fat and, contrary to visfatin, it appears 
to be produced to a greater degree in vascular stromal cells within the fat than in the adipocytes 
themselves. Similar to visfatin, it exerts beneficial effects on glucose uptake, functions as an insulin 
sensitizer, and possesses insulin-mimicking properties [22]. 
Finally, there is apelin, whose receptor is expressed in brain and in nearly all peripheral tissues, 
especially in endothelial cells in cardiac, kidney, lung, adrenal, and endocardial vessels. Apelin causes 
NO-mediated, endothelium-dependent vasodilation and endothelium-independent vasoconstriction by 
means of its action on smooth muscle cells. Apelin is produced in proportion to the amount of fat and 
possesses anorectic properties accompanied by increased body temperature and locomotor activity, as 
well as inhibiting the secretion of glucose-dependent insulin [11]. Int. J. Mol. Sci. 2011, 12                       
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6. Lipotoxicity 
Adipocytes of patients with obesity have a lower insulin receptor density and a higher density of 
beta-3 adrenergic receptors, thus increasing the lipolysis rate with release of FFA, a situation that has 
several  metabolic  consequences  in  which  the  following  are  present:  increase  in  the  production  of 
oxygen-derived  free  radicals;  induction  of  insulin  resistance;  synergism  in  the  action  of  IL-6  and  
TNF-α, and induction of apoptosis in pancreatic beta cells; taken together, these effects are categorized 
as  lipotoxicity.  Lipotoxicity  causes  both  anatomical  and  functional  injury  in  different  cell  lines. 
Adipose  tissue  dysfunction  as  well  as  lipotoxicity  comprise  two  mechanisms  that  explain  the 
proinflammatory state and insulin resistance (IR) [11,23]. 
7. Obesity and Oxidative Stress 
ROS occur under physiological conditions and in many diseases and cause direct or indirect damage 
in different organs; thus, it is known that oxidative stress (OS) is involved in pathological processes 
such as obesity, diabetes, cardiovascular disease, and atherogenic processes. It has been reported that 
obesity  may  induce  systemic  OS  and,  in  turn,  OS  is  associated  with  an  irregular  production  of 
adipokines, which contributes to the development of the metabolic syndrome [24]. The sensitivity of 
CRP and other biomarkers of oxidative damage are higher in individuals with obesity and correlate 
directly with BMI and the percentage of body fat, LDL oxidation, and TG levels [25]; in contrast, 
antioxidant defense markers are lower according to the amount of body fat and central obesity [26,27]. 
A research showed that a diet high in fat and carbohydrates induces a significant increase in OS stress 
and inflammation in persons with obesity [28]. 
Pathophysiology of OS: 
(a) Peroxisomal  fatty  acid  metabolism,  in  which  H2O2  is  formed  as  a  byproduct,  and  despite  
that  peroxisomes  contain  high  catalase  activity,  they  may  cause  OS  under  certain  
pathological conditions. 
(b) Cytochrome  P450  microsomal  reactions,  which  catalyze  the  metabolism  of  xenobiotic 
compounds by oxidoreducers, forming superoxide anion as a byproduct, which can cause OS. 
(c) Phagocyte cells, which attack invasive pathogens with a mixture of ROS and other oxidants. 
This is an immune response, but also damages surrounding tissues, producing inflammation. 
(d) The mitochondrial respiratory chain. It is considered that the mitochondria are the site within 
the  cell  where  the  largest  amount  of  ROS  are  generated,  causing  defects  in  mitochondrial 
metabolism and diseases. 
OS biomarkers, such as malondialdehyde (MDA) and F-2 isoprostanes (F2-IsoPs), are the products 
of  the  peroxidation  of  polyunsaturated  fatty  acids.  One  study  showed  that  BMI  was  significantly 
related  with  the  concentration  of  F2-IsoPs.  In  addition,  dietary  factors  were  analyzed,  and  it  was 
observed that fruit consumption is inversely associated with the level of lipid peroxidation. This same 
study revealed that females demonstrated a higher peroxidation level compared with males, which may 
be caused by the higher percentage of fat possessed by females. We also found a positive relationship 
between lipid peroxidation level and plasma cholesterol concentration [29]. Int. J. Mol. Sci. 2011, 12                       
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Another  OS  marker  is  the  urinary  levels  of  8-iso  Prostaglandin  F2α  (8-iso  PGFα),  which  are 
positively  related  with  obesity  and  insulin  resistance  [30]  and  negatively  associated  with  plasma 
concentration of adiponectin. 
8. Mechanisms of Formation of Free Radicals during Obesity 
8.1. Adipose Tissue  
The increase in obesity-associated OS is probably due to the presence of excessive adipose tissue 
itself,  because  adipocytes  and  preadipocytes  have  been  identified  as  a  source  of  proinflammatory 
cytokines,  including  TNF-α,  IL-1,  and  IL-6;  thus,  obesity  is  considered  a  state  of  chronic 
inflammation.  These  cytokines  are  potent  stimulators  for  the  production  of  reactive  oxygen  and 
nitrogen by macrophages and monocytes; therefore, a rise in the concentration of cytokines could be 
responsible for increased OS. TNF-α also inhibits the activity of PCR, increasing the interaction of 
electrons with oxygen to generate superoxide anion [11]. Adipose tissue also has the secretory capacity 
of angiotensin II, which stimulates Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase 
activity. NADPH oxidase comprises the major route for ROS production in adipocytes [31]. 
8.2. Fatty Acid Oxidation  
Mitochondrial and peroxisomal oxidation of fatty acids are capable of producing free radicals in 
liver  and,  therefore,  OS,  which  could  result  in  mitochondrial  DNA  alterations  in  the  oxidative 
phosphorylation  that  occurs  in  mitochondria,  causing  structural  abnormalities  and  depletion  of 
adenosine  triphosphate  (ATP).  However,  it  is  also  possible  that  mitochondrial  abnormalities  are 
preexisting conditions that allow for overproduction of ROS [32]. 
8.3. Overconsumption of Oxygen 
Obesity increases the mechanical load and myocardial metabolism; therefore, oxygen consumption 
is increased. One negative consequence of increased oxygen consumption is the production of ROS as 
superoxide,  hydroxyl  radical,  and  hydrogen  peroxide  derived  from  the  increase  in  mitochondrial 
respiration and, of course, from the loss of electrons produced in the electron transport chain, resulting 
in the formation of superoxide radical [6,33]. 
8.4. Accumulation of Cellular Damage 
Excessive fat accumulation can cause cellular damage due to pressure effect from fat cells (i.e., non 
alcoholic steatohepatitis). Cellular damage in turn leads to high production of cytokines such as TNF-
α, which generates ROS in the tissues, increasing the lipid peroxidation rate [33]. 
8.5. Type of Diet 
Another possible mechanism of ROS formation during obesity is through diet. Consumption  of 
diets high in fat may alter oxygen metabolism. Fatty deposits are vulnerable to suffering oxidation Int. J. Mol. Sci. 2011, 12                       
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reactions. If the production of these ROS exceeds the antioxidant capacity of the cell, OS resulting in 
lipid peroxidation could contribute to the development of atherosclerosis [33]. 
8.6. Role of Mitochondria in the Development of OS in Obesity 
Mitochondria provide the energy required for nearly all cellular processes that ultimately permit the 
carrying out  of physiological  functions; additionally, they play  a central  role in  cell death  by  the 
mechanism  of  apoptosis.  Mitochondrial  dysfunction  has  been  implicated  in  a  variety  of  diseases 
ranging from neurodegenerative diseases to diabetes and aging. Obesity takes place in disorders that 
affect mitochondrial metabolism, which favors ROS generation and the development of OS. On the 
other hand, another mechanism has been proposed that involves an effect of high triglyceride (TG) on 
the functioning of the mitochondrial respiratory chain, in which intracellular TG, which is also high, 
inhibits translocation of adenine nucleotides and promotes the generation of superoxide [34]. 
The mitochondrial process of oxidative phosphorylation is very efficient, but a small percentage of 
electrons  may  prematurely  reduce  oxygen,  forming  potentially  toxic  free  radicals,  impairing 
mitochondrial function. Beyond that, under certain conditions, protons can be reintroduced into the 
mitochondrial  matrix  through  different  uncoupling  proteins,  affecting  the  control  of  free  radical 
production in mitochondria [35]. Uncoupling proteins possess an amino acid sequence that is utilized 
to  identify  potential  mitochondrial  carriers.  To  date,  three  molecules  have  been  described  in 
mammalian  mitochondria:  UCP-1,  -2,  and  -3.  UCP-1  is  involved  in  the  control  of  adaptive 
thermogenesis and weight control. UCP-3, which in humans is found only in skeletal muscle, appears 
to exert an effect on heat issue, but protects the mitochondria of lipotoxicity in cases of increased 
concentrations  of  FFA  in  the  matrix,  because  it  leads  these  to  the  intermembrane  space.  During 
obesity, an increase in  FFA, which is toxic to pancreatic cells that are sensitive to oxidation and 
inducing alterations in insulin release, may lead to the development of DM [34]. The potential roles of 
UCP-2 include control of ATP synthesis, regulation of fatty acid metabolism, and, thereby, control of 
ROS 3- production; it is also postulated that UCP-2 can mobilize the FAA outside of the mitochondrial 
matrix; FAA are detrimental to the proper functioning of this organelle [36]. 
9. Complications-generated Oxidative Stress in Obesity 
Obesity and the consequent production of OS have been associated with the development of other 
pathologies (Table 1), the most straightforward of which is the metabolic syndrome. 
Table 1. Diseases associated with obesity. 
Insulin resistance and diabetes 
Systemic arterial hypertension 
Ischemic heart diseases 
Obstructive sleep apnea, asthma 
Gout 
Peripheral vascular disease 
Psychology problems (social stigmatization) 
Rheumatological and orthopedics problems 
Oncology problems 
Liver failure Int. J. Mol. Sci. 2011, 12                       
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Another of the changes related with obesity is the development of non-alcoholic steatohepatitis, 
which appears as a result of the increased circulating FFAs that are released by adipose tissue in 
response to insulin resistance. The amount of internalized FFA in liver is not regulated; thus, it is 
proportional  to  the  plasma,  in  addition  it  also  increases  lipogenesis  in  the  body  and  enhances 
intracellular accumulation of TG [34]. Excessive accumulation of fat (TG) in the liver is the first step 
in  the  development  of  non-alcoholic  fatty  liver  disease,  while  the  second  step  is  inflammation  
and cirrhosis.  
10. Obesity and Antioxidant Capacity 
When obesity persists for a long time, antioxidant sources can be depleted, decreasing the activity 
of enzymes such as superoxide dismutase (SOD) and catalase (CAT) [6]. The activity of SOD and 
glutathione peroxidase (GPx) in individuals with obesity is significantly lower compared with that in 
healthy persons, having implications for the development of obesity-related health problems [37]. A 
study  in  rats  showed  that  the  liver  concentration  of  vitamin  A  having  antioxidant  activity  was 
significantly lower in rats with obesity compared with those without obesity; the concentration of 
vitamin A in rats with obesity probably indicates the dilution of this fat-soluble vitamin in high liver 
lipid storage [38]. In addition to vitamin A, levels of serum antioxidants, such as vitamin E, vitamin C, 
and β-carotene, as well as glutathione, are decreased in obesity [39]. In addition to this, ROS decrease 
the expression of adiponectin, suggesting that treatment with antioxidants or ROS inhibitors could 
restore the regulation of adipokines [40]. Thus, supplementation with antioxidants would reduce the 
risk of complications related with obesity and OS [41]. 
11. Nitric Oxide in Obesity 
Nitric oxide  (NO) is  a  physiological  regulator  of diverse functions  in  several tissues including 
cardiovascular, neuromuscular, neurological, genitourinary, gastrointestinal, and renal. Inhibitors of 
nitric oxide synthase (INO) reduce NO production and prevent the decrease in insulin secretion caused 
by free fatty acids [42]. NO is an important anti-atherogenic agent and it inhibits platelet activation and 
aggregation,  leukocyte  chemotaxis,  and  endothelial  adhesion  [43].  Endothelium-dependent 
vasodilation of NO is impaired under conditions of overweight and obesity, which is observed equally 
in the presence of hypercholesterolemia [44]. 
An increase in the production of superoxide as well as the expression of endothelial NO production 
may  increase  peroxynitrite  in  persons  with  obesity  and  high  blood  pressure,  diminishing  the 
availability of NO and causing vasoconstriction in the vasculature of the liver [45]. 
12. Inflammation and Obesity 
This is called low-intensity chronic inflammation to the inflammatory response and it lasts several 
days, weeks, or months in response to the presence of foreign agents in the bloodstream; it is also 
defined as a protective reaction of vascular connective tissue to injurious stimuli including infection. 
There is a clear-sightedness not only that a low-intensity chronic inflammation co-exists, but also that 
it precedes the development of T2DM; one example is the presence of markers that have predictive Int. J. Mol. Sci. 2011, 12                       
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capacity in relation to T2DM, such as PCR and IL-6. Inflammation is characterized by vasodilation, 
vascular permeability, and inflammatory cells such as neutrophils and cytokines [46]. 
Inflammation is  a manifestation of increased OS, which increases  in  subjects  with  obesity and 
which  is  related  with  insulin  resistance  and  endothelial  dysfunction.  These  changes  may  interact 
among  themselves  and  amplify,  producing,  in  this  manner,  the  set  of  metabolic  and  vascular  
alterations [11]. One possible explanation for adipose tissue producing adipokines and acute phase 
proteins  is  the  consideration  of  hypoxia  as  the  trigger.  Hypoxia  would  be  produced  during  the 
overgrowth of adipose tissue during obesity. Adipose tissue produces 25% of systemic IL-6; thus, it is 
said that this adipose tissue may induce a lesser degree of systemic inflammation in persons with 
excess body fat. The overall evidence indicates that, compared with macrophages, fat cells have a 
capacity equal to or greater than inflammatory cells, and it has been observed that the increase of the 
factors released by adipocytes may be reflected in systemic inflammation [47]. Nishimura et al. [48] 
suggest that obese adipose tissue activates CD8(+) T-cells, which, in turn, promote the recruitment and 
activation of macrophages in this tissue. These results support the notion that CD8 (+) T-cells play an 
essential role in the initiation and propagation of adipose inflammation. Cani et al. [49] demonstrated 
that  in  high-fat  diet-fed  mice,  the  modulation  of  gut  microbiota  is  associated  with  an  increased 
intestinal permeability that precedes the development of metabolic endotoxemia, inflammation, and 
associated  disorders,  and  found  that  in  ob/ob  mice,  gut  microbiota  determines  plasma  LPS 
concentration and is a mechanism involved in metabolic disorders. 
13. Endothelial Dysfunction 
The vascular endothelium is a paracrine, endocrine, and autocrine organ that is indispensable for the 
regulation of vascular tone and the maintenance of vascular homeostasis. Endothelial dysfunction is 
characterized by a reduction in the bioavailability of vasodilators, particularly NO, and an increase in 
endothelium-derived contractile factors. It also includes a specific state of endothelial activation that is 
characterized by a proinflammatory, proliferative, and procoagulant state, all favoring atherogenesis [50]. 
Endothelial dysfunction can be caused by stimulating inflammation and free radicals and cytokines; 
LDL oxidation is also associated with an increase in the expression of adhesion molecules in the 
endothelium,  which  facilitates  monocyte  infiltration  into  the  subendothelial  space  [51].  The 
polymerase chain reaction (PCR) favors lower NO activity by increasing the production of factors that 
inhibit the latter’s functions, such as endothelin and angiotensin II, thereby reducing the beneficial 
actions exerted by NO on vascular function [14]. Recently, the role of adipose tissue and its secretory 
adipokine  as  a  major  cause  of  endothelial  dysfunction  has  been  emphasized.  Adipose  tissue 
dysfunction,  as  occurs  in  obesity  and  insulin  resistance,  is  characterized  by  the  activation  of  an 
inflammatory signal. Some of these signals arise, directly or indirectly, from substances secreted in 
adipose tissue. ROS are generated at sites of inflammation and damage; a high concentration of these 
can cause cell damage and death, and specifically, OS increases vascular endothelial permeability and 
promotes leukocyte adhesion [50]. During obesity, there is a higher content of superoxide radicals and 
nitrotyrosine in the coronary endothelium, and early obesity is characterized by increased OS and 
endothelial dysfunction associated with increased leptin levels [52]: in addition, it has been reported Int. J. Mol. Sci. 2011, 12                       
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that  weight  loss  improves  endothelium-dependent  vasodilatation,  improves  endothelial  activation 
markers, and decreases proinflammatory cytokine levels [50]. 
14. Conclusions 
Adipose tissue is a secretory organ of great importance for the organism because the substances that 
it  secretes  meet  the  requirements  for  specific  biological  functions.  As  obesity  is  characterized  by 
excessive storage of adipose tissue, adipokine secretion is increased; therefore, the effects produced in 
the body are altered, and resistance to its effect can be generated, as in the case of leptin. In addition to 
adipokines, we also found an overproduction of ROS, which damage cellular structures and trigger, 
together  with  underproduction  of  NO,  progressive  accumulation  of  fat  and,  eventually,  the 
development of other pathologies. On the other hand, it was observed that the decrease in body fat 
reflected in weight improves oxidation markers and increases antioxidant activity, which was impaired 
with obesity. Therefore, weight loss through nutritional and pharmacological treatment, in addition to 
supplementation with antioxidant nutrients such as vitamins E, A, and C, flavonoids, among others, 
may be the key to reducing the risk of developing other pathologies related with OS and obesity such 
as high blood pressure and, of course, metabolic syndrome. 
Obesity is a condition that is epidemic and that has increased in recent decades. Parallel to the 
increase of this disease, the study of obesity has undergone considerable development. This has been 
accomplished  thanks  to  research  in  various  fields  of  knowledge  that  have  broken  down  multiple 
archetypes, allowing changes in views on overweight, adipose tissue function, and the pathophysiology 
of  the  disease  that  prevail  at  present.  The  breakdown  of  old  paradigms  and  the  new  knowledge 
platform provide a solid foundation for understanding the disease and for developing strategies for 
prevention and treatment. 
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